Transcription-targeted gene therapy for androgen-independent prostate cancer

Cancer Gene Therapy

Volumn 9, Issue 5, 2002, Pages 443-452

  Martiniello Wilks, Rosetta ^a,b   Tsatralis, Tania ^a,b   Russell, Peter ^c   Brookes, Diana E ^d   Zandvliet, Dorethea ^d   Lockett, Linda J ^d   Both, Gerald W ^d   Molloy, Peter L ^d   Russell, Pamela J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d CSIRO   (Australia)

Author keywords

GDEPT; Nude mice; Prostate cancer; Prostate specific promoter; Purine nucleoside phosphorylase; Recombinant adenovirus

Indexed keywords

6 METHYL 9 (2 DEOXY BETA DEXTRO ERYTHRO PENTOFURANOSYL)PURINE; ANDROGEN; ANTINEOPLASTIC AGENT; DEOXYADENOSINE DERIVATIVE; MERCAPTOPURINE; PROBASIN; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; ESCHERICHIA COLI; GENE CASSETTE; GENE THERAPY; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REPORTER GENE; SIMIAN VIRUS 40; SURVIVAL TIME; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; ESCHERICHIA COLI; MUS MUSCULUS; SIMIAE; SIMIAN VIRUS 40;

ADENOVIRIDAE; ANDROGENS; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; PLASMIDS; PRODRUGS; PROSTATIC NEOPLASMS; TIME FACTORS; TISSUE DISTRIBUTION; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 85047695122     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700451     Document Type: Article

References (51)

1. Cancer statistics, 1998
2. Gene therapy for prostate cancer
3. Gene therapy for prostate cancer. New perspectives on an old problem
4. Prodrug activation enzymes in cancer gene therapy
5. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
6. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
7. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats
8. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
9. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes; paradigm for a prospective cancer control strategy
10. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
11. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer
12. Induction of potent antitumor natural killer cell activity by herpes simplex virus thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
13. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
14. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line
15. In vivo adenovirus mediated gene transfer of E. coli cytosine deaminase gene to human colon carcinoma derived tumors induces chemosensitization to 5-flurocytosine
16. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
17. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines
18. Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors
19. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene
20. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells
21. Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase
22. Implication of cell kinetic changes during progression of human prostatic cancer
23. In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-prodrug systems delivered by identical adenovirus vectors
24. Relative activity and specificity of promoters from prostate-expressed genes
25. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen
26. Prostate cancer gene therapy
27. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice
28. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model
29. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer
30. Targeted gene delivery by tropism-modified adenoviral vectors
31. Modification of an adenoviral vector with biologically selected peptides: A novel strategy for gene delivery to cells of choice
32. Prostate-specific antigen expression is regulated by an upstream enhancer
33. Defining a function androgen responsive element in the 5′ far upstream flanking region of the prostate specific-antigen gene
34. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans
35. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene
36. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice
37. Establishment of parameters for optimal transduction efficiency and anti-tumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors
38. Treatment of experimental mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene
39. Human epithelial ovarian cancer xenografts into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy
40. Inhibition of establishment of hepatic metastasis in mice by combination gene therapy using both herpes simplex virus-thymidine kinase and granulocyte-macrophage colony stimulating factor genes in murine colon cancer
41. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase
42. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival
43. Combination gene therapy for oral cancer in a murine model
44. Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13
45. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
46. Cloning of the herpes simplex virus 1CP4 gene in an adenovirus vector: Effects on adenovirus gene expression and replication
47. Manipulation of adenovirus vectors
48. Regio- and stereoselective synthesis of 6-methyl-9-(2-deoxy-β-D-erythro-pentofuranosyl) purine
49. Bladder cancer xenografts: A model of tumor cell heterogeneity
50. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter
51. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1